Pronto Diagnostics

Company Overview

Snapshot

Founded in July 1993 by Nir Navot, Pronto Diagnostics operates with 11–50 employees. The company was acquired by Novolog Group in October 2022.

Business overview

Pronto Diagnostics specializes in the development, production, and distribution of genetic testing kits. These kits provide rapid and accurate assays for detecting DNA polymorphisms associated with genetic diseases and predisposition to disease. The company's products, which test for over 35 different DNA variants, are designed for both small-scale and large-scale clinical genetic analysis, meeting international quality standards with European CE mark certification. Pronto Diagnostics serves markets within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology, and Test Diagnostics & Screening.

Strategic signal

In October 2022, Pronto Diagnostics was acquired by Novolog Group, a significant move that signals consolidation within the Health Tech & Life Sciences sector. This acquisition provides Pronto Diagnostics with enhanced resources and market reach, indicating a strategic validation of its genetic testing technology and a potential for accelerated growth under new ownership.

Company Intelligence Q&A

What was a significant corporate milestone for Pronto Diagnostics?

In October 2022, Novolog Group acquired 75% of Pronto Diagnostics for approximately ILS 11 million.

Who founded Pronto Diagnostics?

Pronto Diagnostics was founded by Nir Navot.

When was Pronto Diagnostics founded?

Pronto Diagnostics was founded in July 1993.

What is Pronto Diagnostics' primary business?

Pronto Diagnostics develops, produces, and distributes genetic testing kits for the clinical diagnosis of genetic diseases.

What was a key partnership for Pronto Diagnostics in 2018?

In July 2018, Pronto Diagnostics partnered with MNG Laboratories to offer clinical RNA sequencing services in Israel.